Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action
22. April 2020 08:05 ET
|
Cocrystal Pharma, Inc.
- Expanded license agreement with KSURF further broadens and advances Cocrystal’s COVID-19 program - - Small molecule therapeutic inhibitors against coronaviruses included in agreement have...